1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents

Journal of Medicinal Chemistry

Volumn 40, Issue 11, 1997, Pages 1634-1647

  Khanna, Ish K ^a   Weier, Richard M ^a   Yu, Yi ^a   Xu, Xiang D ^a   Koszyk, Francis J ^a   Collins, Paul W ^a   Koboldt, Carol M ^a   Veenhuizen, Amy W ^a   Perkins, William E ^a   Casier, Jacquelen J ^a   Masferrer, Jaime L ^a   Zhang, Yan Y ^a   Gregory, Susan A ^a   Seibert, Karen ^a   Isakson, Peter C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; DRUG SPECIFICITY; DRUG SYNTHESIS; GASTROINTESTINAL TOXICITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EDEMA; GASTROINTESTINAL DISEASES; HUMANS; IMIDAZOLES; ISOENZYMES; MEMBRANE PROTEINS; MICE; MOLECULAR STRUCTURE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONES;

EID: 0030919185     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9700225     Document Type: Article

References (74)

1. (a) Insel P. A. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W., Gilman, A. G., Eds.; McGraw-Hill: New York, 1996; pp 617-658.
2. (b) Lombardino, G. Nonsteroidal Antiinflammatory Drugs; Wiley Interscience, John Wiley & Sons: New York, 1985.
3. (a) Vane, J. R. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs. Nature (New Biol.) 1971, 237, 232-235.
4. (b) Smith, J. B.; Willis, A. L. Aspirin Selectivity Inhibits Prostaglandin Production in Human Platelets. Nature (New Biol.) 1971, 231, 235-237.
5. (a) Allison, M. C.; Howatson, A. G.; Torrence, C. J.; Lee, F. D.; Russel, R. I. Gastrointestinal Damage Associated wiith the Use of Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med. 1992, 327, 749-754.
6. (b) Sontag, S. J. Prostaglandins in Peptic Ulcer Disease. An Overview of Current Status and Future Directions. Drugs 1986, 32, 445-457.
7. (c) Schoen, R. T.; Vender, R. J. Mechanisms of Nonsteroidal Antiinflammatory Drug Induced Gastric Damage Am. J. Med. 1989, 86, 449-458.
8. (a) Patrono, C.; Dunn, M. J. The Clinical Significance of Inhibition of Renal Prostaglandin Synthesis. Kidney Int. 1987, 32, 1-12.
9. (b) Clive, D. M.; Stoff, J. S. Renal Syndromes Associated with Nonsteroidal Antiinflammatory Drugs N. Engl. J. Med. 1984, 310, 563-572.
10. (a) Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. Sulindac: A Review of its Pharmacological Properties and Therapeutic Efficacy in Rheumatic Diseases. Drugs 1978, 16, 97-114.
11. (b) Matsuda, K.; Tanaka, Y.; Ushiyama, S.; Ohnishi, K.; Yamazaki, M. Inhibition of Prostaglandin Synthesis By Sodium 2-[4-(2-Oxocyclopentyl methyl)phenyl]propionate Dihydrate (CS-600), A New Antiinflammatory Drug, and Its Active Metabolite In Vitro And In Vivo. Biochem. Pharmacol. 1984, 33, 2473-2478.
12. (c) Friedel, H. A.; Todd, P. A. Nabumetone: A Preliminary Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Rheumatic Diseases. Drugs 1988, 35, 504-524.
13. (d) Ankersen M.; Senning, A. Aspirin Prodrugs: Synthesis and Hydrolysis of 2-Benzyloxy-2-methyl-4H-1,3-benzodioxin-4-ones. Acta Chem, Scand. 1989, 43, 793-798.
14. (e) Bohl, D.; Gaussmann, H.; Vorberg, G.; Sanchez, J.; Garcia-Barbal, R.; Sarti, J. F.; Harrison, F. J. J. A Clinical Trial Comparing A New NSAID (Droxicam) and Piroxicam in Spinal Osteoarthritis. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990, 25, 416-419.
15. (f) Boltze, V. K.-H.; Brendler, O.; Jacobi, H.; Opitz, W.; Raddatz, S.; Seidel, P.-R.; Vollebrecht, D. Chemische Struktur und Antiphlogisistische Wirkung in der Reihe der Substituierten Indol-3-Essigsauren. Arzneim-Forsch. 1980, 30, 1314-1325.
16. (a) Lichtenberger, L. M.; Wang, Z.-M.; Romero, J. J.; Ulloa, C.; Perez, J. C.; Giraud, M.-N.; Bareto, J..C. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Associate With Zwitterionic Phospholipids: Insight Into the Mechanism and Reversal of NSAID-Induced Gastrointestinal Injury. Nature Med. 1995, 1, 154-158.
17. (b) Penkler, L. J.; Glintenkamp, L.-A.; Bodley, M. D.; VanOudtshoom, M. C. B.; Stubbs, C. Pharmaceutical Composition European Patent Publication WO 9532737, 1995.
18. (c) Shelley, R. S.; Wei, Y. Solutions of Aryl or Heteroaryl Substituted Alkanoic Acids in Lipophilic Solvents and Soft Gelatin Capsules Containing Such Solutions. European Patent Publication WO 9531979, 1994.
19. (a) Schimmer, B. P.; Parker, K. L. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J. G., Limbird, L. E., Molinoff, P. B.; Ruddon, R. W.; Gilman, A. G., Eds.; McGraw-Hill: New York, 1996; pp 1459-1486.
20. (b) Masferrer, J. L.; Seibert, K.; Zweifel, B. S.; Needleman, P. Endogenous Glucocorticoids Regulate an Inducible Cyclooxygenase Enzyme, Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3917-3921.
21. (c) Kujubu, D. A.; Herschman, H. Dexamethasone Inhibits Mitogen Induction of the TIS10 Prostaglandin Synthase/Cyclooxygenase Gene. J. Biol. Chem. 1992, 267, 7991-7994.
22. Hla, T.; Neilson, K. Human Cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7384-7388.
23. Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a Mitogen-Response Gene Encoding Prostaglandin Synthase is Regulated by mRNA Splicing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696.
24. Kujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, a Phorbol Ester Tumor Promoter-Inducible mRNA From Swiss 3T3 Cells, Encodes a Novel Prostaglandin Synthase/Cyclooxygenase Homologue. J. Biol. Chem. 1991, 266, 12866-12872.
25. (a) Masferrer, J. L.; Zweifel, B. S.; Manning, P. T.; Hauser, S. D.; Leahey, K. M.; Smith, W. G.; Isakson, P. C.; Seibert, K. Selective Inhibition of Inducible Cyclooxygenase-2 In Vivo is Antiinflammatory and Nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3228-3232.
26. (b) Seibert, K.; Masferrer, J. L. Role of Inducuble Cyclooxygenase (COX-2) in Inflammation. Receptor 1994, 4, 17-23.
27. (a) Meade, E. A.; Smith, W. L.; DeWitt, D. L. Differential Inhibition of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozymes by Aspirin and Other Nonsteroidal Antiinflammatory Drugs J. Biol. Chem. 1993, 268, 6610-6614.
28. (b) Mitchell, J. A.; Akarasereemont, P.; Thiemerman, C.; Flower, R. J.; Vane, J. R. Selectivity of Nonsteroidal Antiinflammatory Drugs as Inhibitors of Constitutive and Inducible Cyclooxygenase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 11693-11697.
29. (c) Vane, J. R.; Mitchell, J. A.; Appleton, I.; Tomlinson, A.; BishopBailey, D.; Croxtail, J.; Willoughby, D. A. Inducible Isoforms of Cyclooxygenase and Nitric-Oxide Synthase in Inflammation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2046-2050.
30. Harada, Y.; Hatanaka, K.; Saito, M.; Majima, M.; Ogina, M.; Kawamura, M.; Ohno, T.; Yang, Q.; Katori, M.; Yamamoto, S. Detection of Inducible Prostaglandin H Synthase-2 in Cells in the Exudate of Rat Carrageenan Induced Pleurisy. Biomed. Res. 1994, 15, 127-130.
31. (a) Emery, P. Clinical Implications of Selective Cyclooxygenase-2 Inhibition. Scand. J. Rheumatol. 1996, 25 (Suppl. 102), 23-28.
32. (b) Carabaza, A.; Cabre, F.; Rotllan, E.; Gomez, M.; Gutierrez, M.; Garcia, L.; Mauleon, D. Stereoselective Inhibition of Inducible Cyclooxygenase by Chiral Nonsteroidal Antiinflammatory Drugs. J. Clin. Pharmacol. 1996, 36, 505-512.
33. (c) Gierse, J. K.; McDonald, J. J.; Hauser, S. D.; Rangwala, S. H.; Koboldt, C. M.; Seibert, K. A Single Amino Acid Difference Between Cyclooxygenase-1 (COX-1) and -2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors. J. Biol. Chem. 1996, 277, 15810-15814.
34. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of SC-58635 (Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
35. (a) Engelhardt, G.; Homma, D.; Schlegel, K.; Utzmann, R.; Schnitzler, C. Antiinflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam. A New Nonsteroidal Antiinflammatory Agent With Favourable Gastrointestinal Tolerance. Inflamm. Res. 1995, 44, 423-433.
36. (b) Tsai, R.-S.; Carrupt, P.-A.; Tayar, N. E.; Giroud, Y.; Andrade, P.; Testa, B. Physiochemical and Structural Properties of Nonsteroidal Antiinflammatory Oxicams. Helv. Chim. Acta 1993, 76, 842-854.
37. (c) Trummlitz, G.; Engelhardt, G.; Busch, U. Meloxieam. Drugs Future 1989, 14, 1047-1048.
38. (a) Gans, K. R.; Galbraith, W.; Roman, R. J.; Haber, S. B.; Kerr, J. S.; Schmidt, W. K.; Smith, C.; Hewews, W. E.; Ackerman, N. R. Antiinflammatory and Safety Profile of DuP 697, A Novel Orally Effective Prostaglandin Synthesis Inhibitor. J. Pharmacol. Exp. Ther. 1990, 254, 180-187.
39. (b) Isakson, P.; Seibert, K.; Masferrer, J.; Salvemini, D.; Lee, L.; Needleman, P. Discovery of a Better AspirinPresented at the Ninth International Conference on Prostaglandin and Related Compounds, Florence, Italy, June 1994.
40. (a) Reitz, D. B.; Li, J J.; Norton, M. B.; Reinhard, E. J.; Collins, J. T.; Anderson, G. D.; Gregory, S.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Isakson, P. C. Selective Cyclooxygenase Inhibitors: Novel 1,2-Diarylcyclopentenes are Potent and Orally Active COX-2 Inhibitors. J. Med. Chem. 1994, 37, 3878-3881.
41. (b) Reitz, D. B.; Huang, H.-C.; Li, J. J.; Garland, D. J.; Manning, R. E.; Anderson, G. D.; Gregory, S.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Isakson, P. C. Selective Cyclooxygenase Inhibitors: Novel 4-Spiro 1,2-Diarylcyclopentenes are Potent and Orally Active COX-2 Inhibitors. Biorg. Med. Chem. Lett. 1995, 5, 867-872.
42. (c) Reitz, D. B.; Li, J. J.; Norton, M. B.; Reinhard, E. J.; Huang, H.-C.; Penick, M. A.; Collins, J. T.; Garland, D. J.; Seibert, K.; Koboldt, C. M.; Gregory, S.; Veenhuizen, A.; Zhang, Y.; Isakson, P. C. Novel 1,2-Diarylcyclopentenes are Selective, Potent and Orally Active Cyclooxygenase Inhibitors. Med. Chem. Res. 1995, 5, 351-363.
43. (d) Huang, H.-C.; Li, J. J.; Garland, D. J.; Chamberlain, T. S., Reinhard, E. J.; Manning, R. E.; Seibert, K.; Koboldt, C. M.; Gregory, S. A.; Anderson, G. D.; Veenhuizen, A. W.; Zhang, Y.; Perkins, W. E.; Burton, E. G.; Cogburn, J. N.; Isakson, P. C.; Reitz, D. B. 1,2-Diarylspiro[2.4]heptenes as Orally Active, Highly Selective Cyclooxygenase-2 Inhibitors: Synthesis and Structure-Activity Relationships. J. Med. Chem. 1996, 39, 253-266.
44. (e) Li, J. J.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Collins, J. T.; Garland, D. J.; Gregory, S. A.; Huang, H.-C.; Isakson, P. C.; Koboldt, C. M.; Logusch, E. W.; Norton, M. B.; Perkins, W. E.; Reinhard, E. J.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y.; Reitz, D. B. 1,2-Diarylcyclopentenes as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-Inflammatory Agents. J. Med. Chem. 1995, 38, 4570-4578.
45. (a) Huang, H.-C.; Chamberlain, T. S. Diaryl Indenes and Benzofurans: Novel Classes of Potent and Selective Cyclooxygenase-2 Inhibitors. Bioorg. Med. Chem. Lett. 1995, 5, 2377-2380.
46. (b) Bertenshaw, S. R.; Talley, J. J.; Rogier, D. J.; Graneto, M. J.; Rogers, R. S.; Kramer, S. W.; Penning, T. D.; Koboldt, C. M.; Veenhuizen, A. W.; Zhang, Y.; Perkins, W. E. 3,4-Diarylthiophenes are Selective COX-2 Inhibitors. Bioorg. Med. Chem. Lett. 1995, 5, 2919-2922.
47. (c) Leblanc, Y.; Gauthier, J, Y.; Ethier, D.; Guay, J.; Mancini, J.; Reindeau, D.; Tagari, P.; Vickers, P.; Wong, E.; Prasit, P. Synthesis and Biological Evaluation of 2,3-Diarylthiophenes as Selective COX-2 and COX-1 Inhibitors. Bioorg. Med. Chem. Lett. 1995, 5, 2123-2128.
48. (d) Copeland, R. A.; Williaks, J. M.; Rider, N. L.; Van Dyk, D. E.; Giannaras, J.; Nurnberg, S.; Covington, M.; Pinto, D.; Magolda, R. L.; Trzaskos, J. M. Selective Time Dependent Inhibition of Cyclooxygenase-2. Med. Chem. Res. 1995, 5, 384-393.
49. (e) Pinto, D. J.; Pitts, W. J.; Copeland, R. A.; Covington, M. B.; Trzaskos, J.; Magolda, R. Selective Inhibition of Cyclooxygenase-2: Diaryl Heterocycles vs Classical NSAIDS. Med. Chem. Res. 1995, 5, 394-398.
50. (f) Griswold, D. E.; Adams, J. L. Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date. Med. Res. Rev. 1996, 16, 181-206.
51. (g) Li, J. J.; Norton, M. B.; Reinhard, E. J.; Anderson, G. D.; Gregory, S. A.; Isakson, P. C.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Seibert, K.; Zhang, Y.; Zweifel, B. S.; Reitz, D. B. Novel Terphenyls as Selective Cycolooxygenase-2 Inhibitors and Orally Active Antiinflammatory Agents. J. Med. Chem. 1996, 39, 1846-1856
52. (a) Tanaka, K.; Yoshida, I. N.; Tomita, K.; Masuda, H. Diaryl Pyrroles: A New Series of Anti-inflammatory Agents. Experientia 1972, 28, 937-938.
53. (b) Wilkerson, W. W.; Copeland, R. A.; Covington, M.; Trzaskos, J. M. Antiinflammatory 4,5-Diarylpyrroles. 2. Activity as a Function of Cyclooxygenase-2 Inhibition. J. Med. Chem. 1995, 38, 3895-3901.
54. (c) Wilkerson, W. W.; Copeland, R. A.; Covington, M.; Grubb, M. F.; Hewes, W. E.; Kerr, J. S.; Trzaskos, J. M. Cyclooxygenase-2 Inhibitory 2-Substituted 4,5-Diarylpyrroles. Med. Chem. Res. 1995, 5, 399-408.
55. (d) Wilkerson, W. W.; Galbraith, W.; Gans-Brangs, K.; Grubb, M.; Hewes, W. E.; Jaffee, B.; Kenney, J. P.; Kerr, J.; Wong, N. Antiinflammatory 4,5-Diarylpyrroles: Synthesis and QSAR. J. Med. Chem. 1994, 37, 988-998.
56. Khanna, I. K.; Weier, R. M.; Collins, P. W.; Yu, Y.; Miyashiro, J. M.; Koboldt, C. M.; Veenhuizen, A. W.; Currie, J. L.; Seibert, K.; Isakson, P. 1,2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2. J. Med. Chem. 1997, 40, 1619-1633.
57. (a) Wiseman, E. H.; McIlhenny, H. M.; Bettis, J. W. Flumizole, A New Nonsteroidal Anti-Inflammatory Agent. J. Pharm. Sci. 1975, 64, 1469-1475.
58. (b) Lombardino, J. G.; Wiseman, E. H. Preparation and Antiinflammatory Activity of Some Nonacidic Trisubstituted Imidazoles. J. Med. Chem. 1974, 17, 1182-1188.
59. (a) Sharpe, T. R.; Cherkofsky, S. C.; Hewes, W. E.; Smith, D. H.; Gregory, W. A.; Haber, S. B.; Leadbetter, M. R.; Whitney, J. G. Preparation and Antiarthritic and Analgesic Activity of 4,5-Diaryl-2-(Substitutedthio)-1H-Imidazoles and Their Sulfoxides and Sulfones. J. Med. Chem. 1985, 28, 1188-1194.
60. (b) Pinto, D. J.; Pitts, W. J.; Copeland, R. A.; Covington, M. B.; Trzaskos, J.; Magolda, R. Selective Inhibition of Cycooxygenase-2: Diaryl Heterocycles vs Classical NSAIDS. Med. Chem. Res. 1995, 5, 394-398.
61. Gauthier, J. Y.; Leblanc, Y.; Black, W. C.; Chan, C. C.; Cromlish, W. A.; Gordon, R.; Kennedey, B. P.; Lau, C. K.; Leger, S.; Wang, Z.; Ethier, D.; Guay, J.; Mancini, J.; Riendeau, D.; Tagari, P.; Vickers, P.; Wong, E.; Xu L.; Prasit, P. Synthesis and Biological Evaluation of 2,3-Diarylthiophenes as Selective COX-2 Inhibitors. Part II: Replacing The Heterocycle. Bioorg. Med. Chem. Lett. 1996, 6, 87-92.
62. Garigipati, R. S. An Efficient Conversion of Nitriles to Amidines. Tetrahedron Lett. 1990, 31, 1969-1972.
63. Huang, H.-C.; Reinhard, E. J.; Reitz, D. B. A Novel One-Pot Conversion of Methyl Sulfones to Sulfonamides. Tetrahedron Lett. 1994, 39, 7201-7204.
64. Gierse, J. K.; Hauser, S. D.; Creely, D. P.; Koboldt, C.; Rangwala, S. H.; Isakson, P. C.; Seibert, K. Expression and Selective Inhibition of the Constitutive and Inducible Forms of Human Cyclooxygenase. Biochem. J. 1995, 305, 479-484.
65. (a) Seibert, K.; Zhang, Y.; Leahy, K; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase-2 in Inflammation and Pain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12013-12017.
66. (b) Winter, C. A.; Risley, E. A.; Nuss, G. W. Carrageenan Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs. Proc. Soc. Exp. Biol. Med. 1962, 111, 544-547.
67. Jaffee, B. D.; Kerr, J. S.; Jones, E. A.; Giannaras, J. V.; McGowan, M.; Ackerman, N. R. The Effect of Immunomodulating Drugs on Adjuvant Induced Arthritis in Lewis Rats. Agents Actions 1989, 27, 344-346.
68. See supplementary materials of ref 18a.
69. Morton, H. E.; Leanna, M. R. Synthesis of α-Halomethyl Ketones: Oxidative Hydrolysis of Vinyl Halides. Tetrahedron Lett. 1993, 34, 4481-4484.
70. Dauzonne, D.; Demerseman, P.; Royer, R. A. New Direct Synthesis of Aromatic Nitriles From Aldehydes. Synthesis 1981, 739-740.
71. Bochis, R. J.; Harris, E.; Tolman, R. L. 5-Amino or Substituted Amino 1,2,3-Triazoles. U.S. Patent (Merck) 4,721,791, 1988.
72. Vorbruggen, H.; Krolikiewicz, K. The Introduction of Nitrile-Groups Into Heterocycles and Conversion of Carboxylic Groups Into Their Corresponding Nitriles With Chlorosulfonylisocyanate and Triethylamine. Tetrahedron 1994, 50, 6549-6558.
73. (a) Szczepankiewicz, B. G.; Heathcock, C. H. Total Synthesis of Diplamine, a Cytotoxic Pyridoacridine Alkaloid From a Pacific Tunicate. J. Org. Chem. 1994, 59, 3512-3513.
74. (b) Wallace, R. G. Hydroxylamine-O-Sulfonic Acid - A Versatile Synthetic Reagent. Aldrichchim. Acta 1980, 13, 3.